Regeneron Earnings Top, Biotech Giant Edges Higher

Regeneron Pharmaceuticals (REGN) on on Thursday reported adjusted earnings of $9.89 per share on $2.53 billion in sales for its first quarter. In response, Regeneron stock edged higher.


On average, analysts polled by FactSet expected Regeneron to earn $8.74 per share on $2.53 billion in sales.

In the year-earlier period, Regeneron earnings were $6.60 per share and the company reported $1.83 billion in sales.

The biotech company did not provide full-year EPS or sales guidance. Analysts called for adjusted income of $46.62 per share and $12 billion in sales.

In premarket trading on the stock market today, Regeneron stock rose 0.7%.

More to follow.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


InMode Stock Rises After IBD 50 Stalwart Posts Triple-Digit Profit Growth

Jazz Expects To Buy GW Pharma — This Month — And Eyes Breakout

Options Trading: How To Start Using Options, How To Manage Risk

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Get Full Access To IBD Stock Lists And Ratings